

**Fiscal Year 2014 (FY14) Defense Medical Research and Development Program
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>FY14 Military Infectious Diseases Applied Research Award (MID-ARA)</p> <p>Go to: Program Announcement General Application Instructions</p> <p>Grants.gov Funding Opportunity Number: W81XWH-14-DMRDP-MID-ARA</p>	<ul style="list-style-type: none"> Independent investigators at all academic levels Intramural and extramural investigators are encouraged to apply 	<p>The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality.</p> <ul style="list-style-type: none"> Preliminary data are required; clinical trials and basic research are <u>not allowed</u> under this mechanism <p>Applications must address at least one of the following MID-ARA Focus Areas:</p> <ul style="list-style-type: none"> Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). 	<ul style="list-style-type: none"> The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is \$2,000,000 in total costs (direct + indirect) A Partnering PI may be included in the application but the combined total funding for both PIs may not exceed \$2,000,000 Subject to availability of funding, approximately 5 MID-ARA applications will be awarded 	<p>Pre-Application: June 10, 2013 5:00 pm Eastern Time (ET)</p> <p>Pre-application is required</p> <p>Application: October 17, 2013 11:59 pm ET</p> <p>Application submission is by invitation only.</p>

		<ul style="list-style-type: none">• Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.		
--	--	---	--	--

<p>FY14 Military Infectious Diseases Clinical Trial Award (MID-CTA)</p> <p>Go to: Program Announcement General Application Instructions</p> <p>Grants.gov Funding Opportunity Number: W81XWH-14-DMRDP-MID-CTA</p>	<ul style="list-style-type: none"> • Independent investigators at all academic levels • Intramural and extramural investigators are encouraged to apply 	<p>The FY14 DMRDP MID-CTA is intended to support early phase clinical trials/testing with the potential to have a major impact on treatment of combat-related or trauma-induced wound infections.</p> <ul style="list-style-type: none"> • Preliminary data are required; • Must include a clinical trial/testing; preclinical studies are not allowed <p>Applications must address at least one of the following MID-CTA Focus Areas:</p> <ul style="list-style-type: none"> • Therapeutics. Evaluation of optimum preventative or directive therapies for combat-related or trauma-induced wound infections using Food and Drug Administration (FDA) approved drugs, biologics, or devices either alone or in combination. Studies focusing on either new indications of FDA approved drugs/ biologics/devices, or investigational new drugs/biologics/devices will be accepted. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$2,500,000 in total costs (direct + indirect) • A Partnering PI may be included in the application but the combined total funding for both PIs may not exceed \$2,500,000 • Subject to availability of funding, approximately 4 MID-CTA applications will be awarded 	<p>Pre-Application: July 3, 2013 5:00 pm Eastern Time (ET)</p> <p>Pre-application is required.</p> <p>Application: October 17, 2013 11:59 pm ET</p> <p>Application submission is by invitation only.</p>
--	---	--	--	--

		<ul style="list-style-type: none">• Rapid detection of pathogens and/or microbial drug resistance markers. Evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or microbial drug resistance markers in combat-related or trauma-induced wounds. Research outcomes and documentation should support the development of an FDA-regulated device or assay.• Rapid detection of biomarkers. Evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization. Research outcomes and documentation should support the development of an FDA-regulated device or assay.		
--	--	--	--	--